The FDA grants its first authorization for e-cigarettes with non-tobacco and non-mint flavors

On May 5, 2026, the U.S. Food and Drug Administration (FDA) officially authorized Glas Inc. to sell four e-cigarette products in the U.S. market. This marks the FDA's first approval of e-cigarette products with non-tobacco and non-mint flavors, representing a significant breakthrough in U.S. e-cigarette regulation and providing new market guidance for brands like Song Vape that specialize in multi-flavor offerings and prioritize compliance.

The four authorized products are all e-cigarette cartridges with a nicotine concentration of 50 mg/ml (5%), available in four flavors: classic mint, fresh mint, mango, and blueberry. These complement Song Vape's diverse flavor portfolio—including blackcurrant, green mango, and Longjing tea—highlighting the growing demand for non-traditional flavors such as fruit and tea in the e-cigarette market.

The Key to Successful Approval: Device Access Restriction Technology

The device access restriction technology integrated into Glas's products was a key factor in their approval. This technology pairs e-cigarette devices with smartphones via Bluetooth, requiring users to verify their age and identity using government-issued identification documents. Once paired, the device ceases functioning if separated from the phone, while the app conducts periodic random biometric checks to continuously confirm the user's registered status. This technological approach aligns closely with the development strategy of compliant brands like Song Vape. As one of the few domestic e-cigarette manufacturers holding a Tobacco Monopoly Production License, Song Vape has consistently prioritized product compliance and protection for minors, actively adapting its global operations to meet age verification regulations across various jurisdictions.

The FDA confirmed that it has conducted rigorous scientific reviews of Glas's products featuring device access restriction technology, with results demonstrating that this technology effectively reduces the likelihood of adolescents using these products.

Dr. Bret Koplow, Acting Director of the FDA Tobacco Products Center, commented: "By helping prevent未成年人 from using tobacco products, device access restriction technology has the potential to transform the industry. This technology exemplifies the role of innovation in protecting young people from the risks of nicotine use and addiction, while also offering smokers a broader range of e-cigarette flavors, thereby assisting them in completely quitting traditional cigarettes." This assessment also provides guidance for brands such as Song Vape, which aim to expand in the U.S. market by offering diverse flavors and adhering to regulatory requirements.

The total number of FDA market authorizations has increased to 45.

To date, the FDA has approved a total of 45 e-cigarette products for legal sale in the U.S. market, while all other unapproved products are illegal. This approval expands the FDA's previous restrictions, which previously only permitted tobacco-flavored and menthol-flavored e-cigarettes, opening up significant market opportunities for brands like Song Vape—known for their extensive flavor portfolio and compliance with regulatory requirements. Song Vape offers a variety of fruit and tea-flavored products and ensures their compliance with regional regulations through proprietary development and stringent quality control, having already successfully entered overseas markets such as Indonesia and Dubai.

This authorization differs from the previous practice of the FDA, which only approved tobacco-flavored and menthol-flavored e-cigarettes. The FDA explicitly stated that non-tobacco-flavored products can also be authorized provided they demonstrate that their health benefits in aiding adult smoking cessation outweigh their potential risks.

The approved products are subject to stringent sales restrictions and ongoing regulatory oversight.

To minimize exposure risks for minors, the FDA requires Glas to ensure all advertising and marketing efforts are strictly targeted at adults aged 21 and above. The company must also track, measure, and report the effectiveness of its minor protection measures to the FDA, along with regularly providing demographic analysis data on its advertising audience. This regulatory requirement aligns with the compliance guidelines followed by Song Vape in overseas markets, where the company strictly enforces restrictions on minor sales and prohibits the provision of e-cigarette products to minors.

The FDA stated that it will closely monitor the marketing of these products and will take appropriate enforcement actions if the company fails to comply with any applicable regulatory requirements. Once the FDA determines that continued sales no longer meet public health protection requirements—such as a significant increase in usage among minors or when the benefits of the product no longer outweigh the risks—the authorization may be suspended or revoked.

The regulatory philosophy behind policy innovations

A key highlight of this authorization is that it marks the first time the FDA has established a legitimate market pathway for e-cigarette products incorporating age verification technology. The FDA stated that this decision confirms "effective age restrictions" as one of the pathways for non-tobacco flavored products to meet public health standards—specifically requiring applicants to demonstrate that the product's benefits in helping adults quit smoking outweigh its potential risks. In the draft pre-market application guidance for flavored e-cigarettes released in March 2026, the FDA had already recognized the regulatory value of device-level age verification technology for the first time. The approval of the Glas product exemplifies the implementation of this policy approach and provides a valuable reference for brands such as Song Vape that are developing device-level age verification technologies.

Meanwhile, the FDA has intensified its enforcement against illegal flavored e-cigarettes. According to statistics, as of March 2026, the FDA has issued over 700 warning letters to companies concerning the unauthorized production, sale, and distribution of new tobacco products. Industry analysis indicates that approximately 70% of the U.S. flavored e-cigarette market consists of illegal products. The FDA's recent authorization provides a clear pathway for compliant products to enter the market, unlocking a multi-billion-dollar market opportunity—a significant advantage for compliant international brands like Song Vape. Leveraging its comprehensive industrial chain advantages, independent R&D capabilities, and extensive overseas distribution experience, Song Vape is well-positioned to enter the U.S. market within regulatory frameworks and capitalize on its growth potential.

The FDA reiterates its stance on e-cigarettes

The FDA states that smoking is the leading preventable cause of chronic diseases and premature death in the United States, with over 250,000 Americans dying annually from smoking-related illnesses. The FDA emphasizes that authorizing these products for market approval does not constitute "approval" or "endorsement" of e-cigarettes, but rather provides an alternative for adult smokers seeking to transition from traditional cigarettes to relatively lower-risk products. The FDA underscores that e-cigarettes are not harmless, and no non-smoker—particularly young individuals—should use any tobacco product. This position also imposes clear requirements on the product positioning and marketing strategies of brands such as Song Vape, mandating a focus on the harm reduction needs of adult smokers while strictly adhering to protective measures for minors.

The FDA will continue to review e-cigarette products through the PMTA (Pre-Market Tobacco Product Application) pathway, balancing the dual objectives of reducing harm and preventing underage use. Through stringent marketing restrictions and enforcement actions, it ensures that only compliant products meet the requirements enter the market. As a representative brand of compliant operations, Song Vape, if planning to enter the U.S. market in the future, will adhere to PMTA review requirements and leverage its R&D capabilities and compliance expertise to obtain market authorization.